EYP001a

Phase 1Small molecule

EEnyo Pharma

EYP001a is one of 63 small molecule programs targeting Hepatitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

Chronic HepatitisActive, not recruiting

HepatitisPhase 1

Active, not recruiting

Chronic HepatitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Sovaldi

Gilead

Preclinical

34 3

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 4

Incivek

Vertex Pharmaceuticals

Preclinical

10 5

Intron a

Sanofi

Preclinical

7 6

Roferon-a

Roche

Preclinical

3 7

Medrol

Pfizer

Preclinical

1 8

SOF/VEL

Gilead

Preclinical

4 9

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

1 10

Pegintron

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis2 trials

A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir

Completed·EEnyo Pharma·Phase 2·NCT04365933·20 enrolled

EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) Infection

Completed·EEnyo Pharma·Phase 1·NCT03320616·11 enrolled

HBV1 trial

Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects

Completed·EEnyo Pharma·Phase 1·NCT03272009·73 enrolled

Tics1 trial

Study Evaluating Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects

Completed·EEnyo Pharma·Phase 1·NCT03110276·80 enrolled

Hepatitis1 trial

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients

Completed·EEnyo Pharma·Phase 1·NCT03976687·16 enrolled

ESS1 trial

Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)

Terminated·EEnyo Pharma·Phase 2·NCT04465916·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for EYP001a. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EYP001a compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EYP001a. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Enyo Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EEnyo Pharma

EYP001a

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Hepatitis2 trials

HBV1 trial

Tics1 trial

Hepatitis1 trial

ESS1 trial

References

Drug Info

Quick Facts

Related News